These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Identification of pharmacoresistant epilepsy. Berg AT Neurol Clin; 2009 Nov; 27(4):1003-1013. PubMed ID: 19853220 [TBL] [Abstract][Full Text] [Related]
3. Pharmacoresistance and the role of surgery in difficult to treat epilepsy. Wiebe S; Jette N Nat Rev Neurol; 2012 Dec; 8(12):669-77. PubMed ID: 22964510 [TBL] [Abstract][Full Text] [Related]
5. The intrinsic severity hypothesis of pharmacoresistance to antiepileptic drugs. Rogawski MA Epilepsia; 2013 May; 54 Suppl 2():33-40. PubMed ID: 23646969 [TBL] [Abstract][Full Text] [Related]
6. Is there a place for surgical treatment of nonpharmacoresistant epilepsy? Steinhoff BJ; Staack AM Epilepsy Behav; 2019 Feb; 91():4-8. PubMed ID: 29960857 [TBL] [Abstract][Full Text] [Related]
7. [Pharmacoresistant epilepsy - epidemiology and current studies]. Pierzchala K Neurol Neurochir Pol; 2010; 44(3):285-90. PubMed ID: 20648993 [TBL] [Abstract][Full Text] [Related]
8. Predictive factors for early identification of pharmacoresistant epilepsy. Sporis D; Basić S; Susak I; Colak Z; Marković I Acta Clin Croat; 2013 Mar; 52(1):11-5. PubMed ID: 23837267 [TBL] [Abstract][Full Text] [Related]
9. Targeting pharmacoresistant epilepsy and epileptogenesis with a dual-purpose antiepileptic drug. Doeser A; Dickhof G; Reitze M; Uebachs M; Schaub C; Pires NM; Bonifácio MJ; Soares-da-Silva P; Beck H Brain; 2015 Feb; 138(Pt 2):371-87. PubMed ID: 25472797 [TBL] [Abstract][Full Text] [Related]
10. Homeostatic bioenergetic network regulation - a novel concept to avoid pharmacoresistance in epilepsy. Boison D; Masino SA; Geiger JD Expert Opin Drug Discov; 2011 Jul; 6(7):713-724. PubMed ID: 21731576 [TBL] [Abstract][Full Text] [Related]
11. Impaired mitochondrial energy production: the basis of pharmacoresistance in epilepsy. Yuen AW; Sander JW Med Hypotheses; 2011 Oct; 77(4):536-40. PubMed ID: 21737204 [TBL] [Abstract][Full Text] [Related]
12. Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy. Summers MA; Moore JL; McAuley JW Ann Pharmacother; 2004 Oct; 38(10):1631-4. PubMed ID: 15328394 [TBL] [Abstract][Full Text] [Related]
13. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. Löscher W; Potschka H J Pharmacol Exp Ther; 2002 Apr; 301(1):7-14. PubMed ID: 11907151 [TBL] [Abstract][Full Text] [Related]
14. [Drug-resistant epilepsy]. Nakken KO; Taubøll E Tidsskr Nor Laegeforen; 2009 Oct; 129(19):1986-9. PubMed ID: 19823202 [TBL] [Abstract][Full Text] [Related]
15. New advances in pharmacoresistant epilepsy towards precise management-from prognosis to treatments. Xu C; Gong Y; Wang Y; Chen Z Pharmacol Ther; 2022 May; 233():108026. PubMed ID: 34718071 [TBL] [Abstract][Full Text] [Related]
16. High seizure frequency prior to antiepileptic treatment is a predictor of pharmacoresistant epilepsy in a rat model of temporal lobe epilepsy. Löscher W; Brandt C Epilepsia; 2010 Jan; 51(1):89-97. PubMed ID: 19563347 [TBL] [Abstract][Full Text] [Related]
17. Effect of Oxidative Stress on ABC Transporters: Contribution to Epilepsy Pharmacoresistance. Grewal GK; Kukal S; Kanojia N; Saso L; Kukreti S; Kukreti R Molecules; 2017 Feb; 22(3):. PubMed ID: 28264441 [TBL] [Abstract][Full Text] [Related]
18. Polyamine Modulation of Anticonvulsant Drug Response: A Potential Mechanism Contributing to Pharmacoresistance in Chronic Epilepsy. Beckonert NM; Opitz T; Pitsch J; Soares da Silva P; Beck H J Neurosci; 2018 Jun; 38(24):5596-5605. PubMed ID: 29789377 [TBL] [Abstract][Full Text] [Related]
20. A complex systems view on the current hypotheses of epilepsy pharmacoresistance. Servilha-Menezes G; Garcia-Cairasco N Epilepsia Open; 2022 Aug; 7 Suppl 1(Suppl 1):S8-S22. PubMed ID: 35253410 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]